TransCode Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Philippe Calais
- Full Time Employees
- 12
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 6 Liberty Square Boston MA United States of America 02109
- IPO Date
- Jul 8, 2021
- CIK
- 0001829635
- Website
- transcodetherapeutics.com
- Similar Companies
- Business
- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) develops RNA-based therapeutics targeting metastatic cancer using its proprietary TTX nanoparticle delivery platform; lead candidate TTX-MC138 inhibits microRNA-10b, a master regulator of metastatic cell viability in breast, pancreatic, ovarian, colon, glioblastoma and other cancers; preclinical pipeline includes TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-RIGA, an RNA-based agonist of retinoic acid-inducible gene I to activate innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9 platform for editing cancer-causing genes in tumor cells; TTX-mRNA, an mRNA platform for cancer vaccines eliciting cytotoxic immune responses; and TTX-siMYC, an RNA-based inhibitor of c-MYC oncogene. The company expanded its pipeline in October 2025 through acquisition of Polynoma LLC from CK Life Sciences, adding Phase 3-ready seviprotimut-L, a polyvalent shed antigen vaccine for adjuvant treatment of stage IIB/IIC melanoma; concurrent $25 million equity investment from CK Life Sciences subsidiary, comprising $20 million cash and $5 million note, to fund TTX-MC138 Phase 2 trial initiation; Dr. Philippe P. Calais, Pharm.D., appointed chief executive officer with Tom Fitzgerald transitioning to chief financial officer; CK Life Sciences to hold approximately 91% fully diluted ownership post-closing, valued at $165 million with up to $95 million contingent milestone payments. TransCode Therapeutics operates in the biotechnology sector focusing on oncology; targets patients with metastatic and high-risk early-stage cancers; maintains strategic collaboration with The University of Texas MD Anderson Cancer Center. Founded in 2016, the company is headquartered in Boston, Massachusetts.
Company News
TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up
TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology
TransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer Transcript
TransCode Therapeutics Announces Leadership Transition
TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis
TransCode Therapeutics Stockholders Approve Share Issuance Plans, Board Slate
TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript
TransCode Therapeutics to Host R&D Webcast on June 18, 2026
TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study
TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
4D Molecular Therapeutics (NASDAQ:FDMT) versus TransCode Therapeutics (NASDAQ:RNAZ) Head-To-Head Contrast
Head-To-Head Comparison: Karyopharm Therapeutics (NASDAQ:KPTI) & TransCode Therapeutics (NASDAQ:RNAZ)
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development